Opinion|Videos|December 5, 2025
Payer and Prior Authorization Barriers
Panelists discuss how payer controls and prior authorization policies delay and derail LDL-lowering therapy.
Episodes in this series
Panelists discuss how payer utilization management and prior authorization processes delay therapy initiation and contribute to high abandonment rates.
The paperwork burden discourages prescribers and frustrates patients, often interrupting continuity of care. Panelists highlight that these barriers disproportionately affect lower-income populations and smaller practices.
They recommend policy reforms that balance cost control with clinical flexibility, enabling timely treatment for high-risk individuals.
Related to this article
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
4
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
5